The currently ongoing Trial to Reduce Cardiovascular Events with Aranesp (TREAT) [70] is a double-blind study comparing darbepoetin alfa treatment (Hb target, 13 g/dL) versus placebo in patients with type 2 diabetes and CKD to assess effects on cardiovascular morbidity due to acute myocardial ischemia. The gene discussed is GSTM1; the disease is chronic kidney disease.